Nutrition and immune system in nontuberculous mycobacterial lung disease
Part of Lungs & breathing clinical trials.
This study looks at how your diet (nutrition) and your immune system's T cells (a type of white blood cell) may affect the progression of a lung infection caused by nontuberculous mycobacteria (NTM). Researchers will use samples from a bronchoscopy to check your immune activity and nutrition, which may help understand the disease and guide better care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have or be suspected of having a lung infection caused by nontuberculous mycobacteria (a type of bacteria different from tuberculosis).
- Your regular peroxide must show that you do not have active tuberculosis, and you must not have a latent (hidden) tuberculosis infection.
- You must be scheduled for a bronchoscopy (a procedure to look inside your lungs) as part of your regular care.
- You cannot have certain other conditions, such as active cancer requiring treatment, an autoimmune disease, a recent organ or bone marrow transplant, or be on medications that weaken your immune system.
- You cannot be pregnant or have had a sudden chest infection treated within 4 weeks before the bronchoscopy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether a program of exercise and airway clearance education helps people with nontuberculous mycobacterial (NTM) lung disease. It aims to improve breathing and quality of life.
This trial tests whether a structured exercise program can improve symptoms and quality of life in people with nontuberculous mycobacterial (NTM) lung disease. If you have a confirmed NTM lung infection and are having respiratory symptoms, this study may help you build strength and better manage your condition.
This study checks whether a blood test called soluble programmed death-1 can help predict how nodular-bronchiectatic nontuberculous mycobacterial (NTM) lung disease will progress. Results may help doctors monitor patients more accurately and decide when to treat or follow more closely.
This study looks at the characteristics of nontuberculous mycobacterial (NTM) lung disease and how the bacteria avoid the body's immune system. It helps doctors understand this condition better and improve future treatments.
This study examines how different types of mycobacterial infections (including tuberculosis) affect your body's immune response. Researchers will compare immune function across different TB types and drug-resistance patterns to better understand the disease and improve treatment.
This study looks at the community of tiny organisms in the lungs (the lung microbiome) in people with bronchiectasis caused by NTM (non-tuberculous mycobacteria). It compares people with positive NTM cultures to people without, to better understand what’s going on in the lungs and why symptoms may differ.
Hear when a new Nontuberculous Mycobacterial Pulmonary Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.